methyl-CpG binding domain protein 3Genealiases: []
Q-omics provides the consensus-scored MBD3 profile across patient tissues and cancer cell-line models. MBD3 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, MBD3 is differentially expressed in 13, with the highest sampling consensus in COAD. Additionally, MBD3 protein abundance shows 29,080 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight ACC, COAD, and GBM as cancer lineages where MBD3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MBD3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MBD3 survival associations across molecular data types. MBD3 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (8) and mass-spec protein abundance (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MBD3 RNA expression–survival associations across cancer types. High MBD3 expression shows unfavorable associations in ACC, LIHC, KIRC and KICH, but favorable associations in PAAD and SCLC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for MBD3 RNA expression.
This table summarizes MBD3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 9. The strongest signals are observed in COAD for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for MBD3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MBD3 shows higher tumor expression in COAD, LIHC, STAD, KIRC, HNSC and LUSC. The COAD box plot shows higher MBD3 RNA expression in tumor versus normal tissue (log2 FC = +0.402, t-test p < 0.001).
This table shows molecular features associated with MBD3 in patient tissues and cancer cell lines. In patient samples, MBD3 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, MBD3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and BLOOD_Lymphoma.
